



HAL
open science

In vivo Therapeutic Synergism of Anti-Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas.

Christel Larbouret, Bruno Robert, Isabelle Navarro-Teulon, Simon Thèzenas, Maha-Zohra Ladjemi, Sébastien Morisseau, Emmanuelle Campigna, Frédéric Bibeau, Jean-Pierre Mach, André Pèlegin, et al.

► **To cite this version:**

Christel Larbouret, Bruno Robert, Isabelle Navarro-Teulon, Simon Thèzenas, Maha-Zohra Ladjemi, et al.. In vivo Therapeutic Synergism of Anti-Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas.. *Clinical Cancer Research*, 2007, 13 (11), pp.3356-62. 10.1158/1078-0432.CCR-06-2302 . inserm-00153693

HAL Id: inserm-00153693

<https://inserm.hal.science/inserm-00153693>

Submitted on 5 Jul 2010

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

In vivo therapeutic synergism of anti-EGFR and anti-HER2 monoclonal antibodies against pancreatic carcinomas

Christel Larbouret¹, Bruno Robert^{1,6}, Isabelle Navarro-Teulon^{1,6}, Simon Thèzenas², Maha-Zohra Ladjemi¹, Sébastien Morisseau¹, Emmanuelle Campigna¹, Frédéric Bibeau³, Jean-Pierre Mach⁴, André Pèlegri^{1,7}, and David Azria^{1,5}

¹INSERM, EMI 0227, Centre de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, France; Université Montpellier1, Montpellier, F-34298, France; CRLC Val d'Aurelle – Paul Lamarque, Montpellier, F-34298, France; ²CRLC Val d'Aurelle – Paul Lamarque, Unité de Biostatistiques, Montpellier, F-34298, France; ³CRLC Val d'Aurelle – Paul Lamarque, Département de Pathologie, Montpellier, F-34298, France; ⁴Département de Biochimie, Université de Lausanne, CH-1066 Epalinges, Suisse; ⁵CRLC Val d'Aurelle – Paul Lamarque, Département de Radiothérapie, Montpellier, F-34298, France. ⁶BR and INT contributed equally to this work.

Running title: Anti-HER antibodies in pancreatic cancer

Key words: EGFR, HER2, monoclonal antibodies, therapeutic synergism, pancreatic cancer

Abbreviations: EGFR, EGF receptor; mAb, monoclonal antibody.

⁷Requests for reprints: André Pèlegri, PhD, Centre de Recherche en Cancérologie de Montpellier, CRLC Val d'Aurelle – Paul Lamarque, 34298 Montpellier Cedex 5, France. Phone: +33-467-613-032; Fax: +33-467-613-787; E-mail: apelegri@valdorel.fnclcc.fr

Grant support: INSERM EMI0227 was supported for this project by the CAMPLP. C. Larbouret and this study were supported by the French National League against Cancer and by Merck AG Laboratories, Germany.

Abstract

Purpose: Pancreatic carcinoma is highly resistant to therapy. EGFR and HER2 have been reported to be both dysregulated in this cancer. To evaluate the *in vivo* impact of binding both EGFR and HER2 with two therapeutic humanized monoclonal antibodies (mAbs), we treated human pancreatic carcinoma xenografts, expressing high EGFR and low HER2 levels.

Experimental design: Nude mice, bearing xenografts of BxPC-3 or MiaPaCa-2 human pancreatic carcinoma cell lines, were injected twice a week for four weeks with different doses of anti-EGFR (matuzumab) and anti-HER2 (trastuzumab) mAbs either alone or in combination. The effect of the two mAbs, on HER receptors phosphorylation was also studied *in vitro* by western blot analysis.

Results: The combined mAb treatment significantly inhibited tumor progression of the BxPC-3 xenografts, as compared with single mAb injection ($P= 0.006$) or no treatment ($P= 0.0004$) and specifically induced some complete remissions. The two mAbs had more anti-tumor effect than fourfold greater doses of each mAb. The significant synergistic effect of the two mAbs was confirmed on the MiaPaCa-2 xenograft and on another type of carcinoma, SK-OV-3 ovarian carcinoma xenografts. *In vitro*, the cooperative effect of the two mAbs was associated with a decrease in EGFR and HER2 receptors phosphorylation

Conclusions: Anti-HER2 mAb has a synergistic therapeutic effect when combined with an anti-EGFR mAb on pancreatic carcinomas with low HER2 expression. These observations may open the way to the use of these two mAbs in a large panel of carcinomas expressing different levels of the two HER receptors.

Introduction

The incidence of pancreatic cancer has steadily increased over the past four decades, and its prognosis is still dismal, despite all efforts in early diagnosis and therapy. Even with a complete surgical resection, the five-year survival rate is less than 20% (1). Conventional therapies associating surgery and radiotherapy often in combination with chemotherapy show modest efficacy in local control and palliation, and no real progress in patient survival (2-4). Thus, novel approaches to human pancreatic carcinoma therapy are urgently needed.

Among the numerous biochemical and genetic abnormalities which were found to be associated with this malignancy (3), we were interested by the fact that two receptors of the HER tyrosine kinase family EGFR (ErbB1 or HER1) and HER2 (ErbB2) are expressed in a significant percentage of cases ranging from 45 to 95% for EGFR (5,6) and 43 to 69% for HER2 (7,8). The levels of HER2 expression, however, were low in the majority of tumors. Furthermore, the overexpression of EGFR and HER2 receptors is often caused by encoding gene amplification (9).

EGFR and HER2 are known to play an essential role in regulating cell proliferation and differentiation. They have a strong tendency to assemble with other HER receptors into homo- and/or heterodimers upon extracellular growth factor binding, which results in various forms of signal transduction pathways activation, leading to either apoptosis, survival, or cell proliferation (9,10). Mounting evidence suggests that not only receptor overexpression but also communication among HER receptors plays a crucial role in tumor behavior (11,12). In particular, binding of receptor-specific ligands to the ectodomain of EGFR often results in the recruitment of HER2, as the preferred heterodimerization partner (13-15). As HER2 is the only HER family member that

does not bind a known specific ligand, its principal biological function, as a signal transducer, appears to result from its participation in heterodimeric receptor complexes with EGFR or other HER receptors (14-16).

The use of mAbs binding with high affinity to these two members of the HER family, EGFR and HER2, thus appears to be rational for the development of new cancer therapy strategies which would have the potential to inhibit the receptor dimerization. Until now, however, each of the two mAbs have been used in cancer therapy individually in conjunction with various chemotherapeutic drugs (17,18) or more recently in association with different drugs having tyrosine kinase receptor inhibition properties (16,19). The action of small tyrosine kinase inhibitor molecules, however, cannot be compared with the potential biological activity induced by the binding of a high molecular weight antibody molecule.

The mechanism of anti-tumor activity of individual anti-HER receptor mAbs is not entirely understood. A series of experimental results in mice KO for the Fc receptor strongly suggested that most of the anti-tumor effect was due to the recruitment of effector NK cells by an antibody dependent cell-mediated cytotoxic (ADCC) mechanism (20). However, the evidence of inhibition of receptor phosphorylation and receptor internalization induced on tumor cells by the anti-HER receptor mAbs argues in favor of an apoptotic or cytostatic signal transduced through the receptor (9,21-24).

Concerning anti-EGFR mAbs, such as cetuximab (Erbix) or matuzumab (EMD72000), they were shown to compete with the EGFR ligands and inhibit tumor cell proliferation *in vitro* and in xenograft mouse models. Both mAbs were shown in clinical trials to be well tolerated (18,25) and active mostly in

conjunction with various chemotherapeutic agents, against metastatic colorectal carcinomas (i.e., doxorubicin, adriamycin, taxol, and cisplatin) (18) , leading to approval by the FDA of cetuximab. Interestingly, clinical studies showed that the anti-EGFR mAb had anti-tumor activity even in patients with colorectal carcinomas expressing no detectable amounts of the receptor by immunohistochemistry (26). Thus, a phase II trial of pancreatic carcinoma treatment with the cetuximab anti-EGFR in combination with gemcitabine appeared justified, but the results of 12.2% partial responses were not very encouraging (6).

For anti-HER2 mAbs, their anti-tumor activity is unlikely to be due to an inhibition of ligand binding since no specific ligand for this receptor has been identified (9,14). The therapeutic efficacy of the anti-HER2 mAb, trastuzumab, in breast carcinoma is well demonstrated, but it is strictly limited and only approved for the 30% of tumors overexpressing HER2 (17). Thus, the present day consensus is that anti-HER2 mAb is inefficient in tumors with low HER2 expression, which is the case for most pancreatic carcinoma in the clinic (7,8). Despite this limitation, in view of the known unique biological cooperation and dimerization properties of EGFR and HER2 and the numerous encouraging *in vitro* results (9-16), we decided to evaluate the anti-tumor effect of the combined injection of two high affinity anti-EGFR and anti-HER2 mAbs, matuzumab and trastuzumab. The two-mAb treatment led to far greater tumor regression and mice survival than injection of each of the mAbs alone, suggesting that the two-mAb treatment could overcome some of the limitations encountered in the treatment with trastuzumab of low HER2 expressing tumors. Interestingly, the demonstration of therapeutic synergism of the two mAbs was also confirmed on xenografts from the human ovarian xenograft cell line, SK-OV-

3, known to overexpress both EGFR and HER2, extending the potential broad application of this anti-tumor treatment by two anti-HER receptor mAbs.

Materials and Methods

Monoclonal Antibodies and EGF. Anti-EGFR humanized antibody matuzumab was kindly obtained from Merck AG (Frankfurt, Germany). The anti-HER2 humanized antibody trastuzumab (Herceptin[®]) was purchased from Genentech, Inc. (San Francisco, CA, USA). Recombinant EGF was obtained from Sigma (St. Louis, MO, USA).

Cell Lines and Culture Conditions. Human pancreatic (BxPC-3 and MiaPaCa-2) and ovarian (SK-OV-3) carcinoma cell lines were obtained from the American Type Culture Collection (ATCC; Rockville, MD, USA). The BxPC-3 cell line was cultured in RPMI-1640 medium (Gibco, Paisley, UK); the MiaPaCa-2 and SK-OV-3 cell lines were cultured in DMEM medium (Gibco). The culture media were supplemented as recommended by ATCC.

In vivo Tumor Growth Inhibition Study. All *in vivo* experiments were performed in compliance with the French guidelines for experimental animal studies (Agreement No. B34-172-27). Nude mice, 6–8-week-old female athymic NMRI mice and BALB/c athymic mice were purchased from Janvier, Le Genest (St Isle, France) and Charles Rivers Laboratories (L'Arbresle, France), respectively.

BxPC-3 (3.5×10^6), MiaPaCa-2 (5×10^6) and SK-OV-3 (5×10^6) cells were injected subcutaneously (s.c.) into the right flank of athymic NMRI (BxPC-3 model) and BALB/c (MiaPaCa-2 and SK-OV-3) nude mice. MiaPaCa-2 cells were suspending in 50% culture medium and 50% Matrigel (BD biosciences, Le Pont De claix, France). Tumor-bearing mice were randomized in the different treatment groups when the tumors reached an approximate volume indicated in each experiment. For the BxPC-3 model, effects of antibody treatments were

studied on small tumor (experiment S) and on large tumor (experiment L). The mice were treated by intraperitoneal injections (i.p.) with 0.9% NaCl, trastuzumab, matuzumab, or both mAbs at a ratio of 1:1. The amounts of each injected mAb were 25 μg , 50 μg or 200 μg per injection depending on the experiment, twice a week for four weeks consecutively.

Tumor dimensions were measured twice weekly with a caliper and the volumes calculated by the formula: $D_1 \times D_2 \times D_3 / 2$. Tumor progression was calculated using the formula: $[(\text{final volume}) - (\text{initial volume})] / (\text{initial volume})$. The results were also expressed by an adapted Kaplan-Meier survival curve, using the time taken for the tumor to reach a determined volume of 1000 mm^3 for SK-OV-3, 1500 mm^3 for BxPC-3 and 2000 mm^3 for MiaPaCa-2 xenografts, depending on the rapidity of growth of the tumors. A median delay was defined as the time at which 50% of the mice had a tumor reaching the determined volume. For experiment S in the BxPC-3 model, an increment factor during the treatment period was calculated by dividing the tumor volume at the end of treatment (day 55) by that at the beginning of the treatment (day 27).

Immunohistochemical Analyses. Expression of receptors was analyzed in paraffin-embedded xenograft fixed in AFA (alcohol formol acetic acid). Analysis of EGFR expression was performed by using the EGFR pharmDx kit (DakoCytomation, Carpinteria, CA, USA) according to the manufacturer's recommendations. Diaminobenzidine (Dakocytomation) was used as the chromogen, and the sections were lightly counterstained with hematoxylin. The primary antibody used for the detection of HER2 was a rabbit polyclonal antibody (Dakocytomation).

Flow Cytometry. Cell surface EGFR and HER2 expression was analyzed by flow cytometry (FACs) using the murine anti-EGFR monoclonal antibody (m225; HB8508 ATCC) and trastuzumab, respectively. After washing, an anti-mouse or an anti-human FITC conjugated monoclonal antibody (Sigma Aldrich) was added to detect the primary antibodies. Direct incubation of cells with the secondary antibody was used for background measurements. The samples were analyzed on a FACScan II (Becton Dickinson, Mountain View, CA, USA) by observing a minimum of 20000 events.

Immunoblotting Analysis. BxPC-3, MiaPaCa-2 and SK-OV-3 cells, plated at 10^6 cells for 24 h in Petri dishes were starved for two days in a medium without growth factors (SM medium) and treated with 10 μ g/ml of trastuzumab, matuzumab or both antibodies at a fixed 1:1 ratio (or controls without antibody). After a 48-h incubation, cells were incubated for 10 min in the SM medium with or without 100 ng/ml of EGF, washed twice, and lysed with buffer (CliniSciences SA, Montrouge, France) containing 100 μ M PMSF, 100 mM sodium fluoride, 1 mM sodium orthovanate, and one complete protease inhibitor mixture tablet (Sigma, St Louis, MO).

After electrophoresis on 8% SDS-PAGE under non-reducing conditions, the proteins were transferred to a polyvinylidene difluoride membranes (Millipore Co., Bedford, MA) which were saturated in PBS containing 0.1% Tween 20 and 5% nonfat dry milk and then incubated with the antibodies against the phosphorylated forms of EGFR, HER2, ERK1/2 and AKT obtained from Cell Signaling Technology (Beverly, MA). To ensure equal loading, immunoblots were also probed with anti-GAPDH (*glyceraldehydes-3-phosphate deshydrogenase*) antibody (Chemicon international, Australia).

Statistical Methods. Survival curves were drawn, and the logrank test was performed to assess differences between groups. All reported *P* values are two-sided. For all statistical tests, differences were considered as significant at the 5% level.

Statistical analyses were performed on an IBM PC-compatible personal computer using the STATA 9.0 software (Stata Corporation, College Station, Texas, USA).

Results

EGFR and HER2 Receptor Cell Surface Expressions. Immunohistochemical analyses on BxPC-3 xenografts showed a high level of EGFR (classified as +++) but no detectable levels of HER2 receptor expression, as compared with SK-OV-3 xenograft, classified as +++ for HER2 and ++ for EGFR, respectively (Fig. 1). MiaPaCa-2 xenografts were classified negative for HER2 and ++ for EGFR. In contrast, using the more sensitive flow cytometry technique (27), a moderate expression of HER2 was found on BxPC-3 and MiaPaCa-2 cells as compared with SK-OV-3 cells. The overexpression of EGFR by BxPC-3 cells was confirmed. MiaPaCa-2 showed a moderate and equal expression of both EGFR and HER2 receptors. SK-OV-3 showed a moderate expression of EGFR and a high expression of HER2 (Fig. 1).

Anti-tumor Activity of Matuzumab and/or Trastuzumab Against Two Pancreatic and an Ovarian Carcinoma Xenografts. The therapeutic efficacy of the anti-EGFR and anti-HER2 mAbs alone or in combination was first tested on BxPC-3 xenografts in nude mice. To evaluate the different forms of mAb therapy on tumor xenografts of various sizes, two series of representative experimental results, first on tumors of relatively small volume ($77 \pm 49 \text{ mm}^3$, experiment S) and second with larger tumors ($503 \pm 205 \text{ mm}^3$, experiment L), were analyzed. Results from experiment S (Fig. 2), obtained in groups of eight mice treated with 50 μg of each antibody twice weekly for four weeks, showed a significantly higher inhibition of tumor growth in the combined antibody group as compared to the groups treated with each antibody alone ($P = 0.002$). Further analysis of the same experimental results showed that the tumor increment factors at the end of treatment were markedly higher in the mice treated with anti-EGFR and anti-

HER2 mAb alone, 4.9 ± 2.1 and 6.4 ± 4.4 , as compared with the combined mAb group 0.7 ± 0.5 (Table 1, upper part). Furthermore, only the combined mAb treatment induced two complete tumor remissions.

Results from an additional experiment on mice with similar size BxPC-3 xenografts treated with fourfold greater doses of each mAb (200 μ g) alone or in combination entirely confirmed the previous results, with tumor increment factors much higher for the single mAb treatment, as compared with the combined mAb therapy (Table 1, lower part). In addition, complete tumor remissions in three out of five mice were observed only in the combined therapy group at the end of treatment.

Comparison of therapy with different antibody doses, reported in Table 1, showed that 50 μ g of each mAb in combination induced markedly lower tumor increments (0.7 ± 0.5) than those obtained in mice treated with fourfold greater doses of the single mAb (4.3 and 5.5). No detectable dose effect was observed between the 50 and 200 μ g treatments suggesting that the synergism of the two mAbs binding to the two HER receptors was more important than the absolute amounts of antibody. This observation is clearly in favor of a synergic effect rather than an additive one.

Results from larger xenografts from the BxPC-3 tumors (experiment L) obtained in four groups of six mice injected with 200 μ g of each antibody showed in adapted Kaplan-Meier survival curves (Fig. 3A) that the median delay for tumors to reach 1500 mm³ volume was significantly longer (73 days) in mice treated with the mAb combination than in mice treated with only one mAb (anti-HER2, 30 days, anti-EGFR, 34 days) $P = 0.001$. The time tumor progression curves from the same experiment (Fig. 3B) confirmed that the time to reach a threefold larger tumor was significantly longer ($P < 0.001$) for the combined

treatment group, than for the two single mAb treatments. Interestingly, in an additional group of six mice with large tumors treated with only 50 μg of each mAb in combination, the time (70 days) for the tumor to reach a volume of 1500 mm^3 was much longer as compared with the tumors in the group treated with 200 μg of each mAb alone (30 and 34 days) (Fig. 3A). This confirms that even with the larger tumors the double specificity of the two mAb was more effective than the absolute mAb doses and that the greater anti-tumor effect was due to a synergistic rather than an additive effect of the two mAbs.

The tumor growth inhibition property of the combined anti-EGFR and anti-HER2 mAbs was further tested on xenografts from a second human pancreatic carcinoma line MiaPaCa-2, which also expresses low HER2 levels. Injection twice a week of 50 μg of each mAb alone or in combination was initiated in groups of six mice when the mean tumor volume had reached $64 \pm 5 \text{ mm}^3$ and continued for four weeks. Animals were euthanized when the tumor reached a volume of 2000 mm^3 . The adapted survival curves for tumors to reach this volume show (Fig. 4A) that at day 120, no tumor larger than 2000 mm^3 was observed in the combined antibody group, whereas four out of six mice from both groups treated with a single mAb had tumors reaching that volume ($P = 0.0072$). Furthermore, a complete tumor remission was observed only in the combined mAb therapy group. Interestingly, in a separate experiment, treatment of MiaPaCa-2 xenografts of similar size ($65 \pm 6 \text{ mm}^3$) with only 25 μg of each antibody in combination had an efficient anti-tumor effect (Fig. 4B) similar to the results obtained with 50 μg of antibodies, confirming, for this tumor also, the important role of the attack by two mAbs directed against different HER receptors.

To verify whether the therapeutic advantage of the combined action of the two anti-HER receptor mAbs observed against the two pancreatic carcinoma cell

lines can also function on another type of carcinoma, the same comparison between single and combined mAb injections was tested on the reference ovarian carcinoma line SK-OV-3, known to overexpress both EGF and HER-2 receptors. The therapy consisting of 200 μg of either anti-EGFR or anti-HER-2 mAb, or the two mAbs in combination, was initiated in four groups of six mice (including an untreated control) when the SK-OV-3 xenograft had a median volume of $42 \pm 4\text{mm}^3$. As expected, in view of the overexpression of both HER receptors on these tumor cells, a therapeutic activity of each single mAb was observed with 1 and 2 complete remissions in the group of mice injected with anti-EGFR and anti-HER2, respectively. However, the injection of both mAbs gave a clearly superior tumor growth inhibition in all mice, including three complete remissions. The results of the adapted survival curve for the tumor to reach a volume of 1000mm^3 (Fig. 4C) showed that the tumors of all six mice treated with the mAb combination did not reach 1000mm^3 during the period of observation of 120 days, while the delay for 50% of the mice to reach this tumor volume was 69 days and 85 days for the group of mice treated with anti-EGFR and HER2, respectively ($P = 0.0001$). These results confirmed the therapeutic synergism of the two anti-HER mice mAbs against a human ovarian carcinoma xenograft and suggests that the combined injection of these two mAbs could be useful in the treatment of many types of carcinomas expressing EGF and HER2 receptors.

Inhibition of Receptor Auto-phosphorylation. The ability of matuzumab or trastuzumab used alone or in combination to inhibit the tyrosine kinase activity of EGFR and HER2 on BxPC-3, MiaPaCa-2 and SK-OV-3 cells *in vitro*, was assessed by western blot with quantification of the phosphorylated proteins by

densitometry and analysis using the NIH imager 6.3 (Fig. 5). Analysis on the carcinoma cell lines was compared after a 48-h incubation with the two mAbs, either alone or in combination, followed by a 10-min activation with EGF. It should be noted first, that both pancreatic cell lines showed a relatively high phosphorylation base line for the EGFR and the HER2 receptor and SK-OV-3 cell line a high phosphorylation base line for HER2 receptor. As expected, treatment with exogenous EGF induced an increased level of tyrosine auto-phosphorylation of EGFR and HER2 in both pancreatic carcinoma cell lines, BxPC-3 and MiaPaCa-2. Interestingly, incubation with the two mAbs in combination resulted in a much higher inhibition of phosphorylation of HER2 than that obtained with anti-HER2 mAb alone in both pancreatic carcinoma cell lines. In SK-OV-3 cell line, however, treatment with trastuzumab alone or in combination with matuzumab reduced the HER2 phosphorylation to a similar extent.

For EGFR, the phosphorylation inhibition by the two mAbs was almost identical or only slightly superior to that obtained with the anti-EGFR mAb alone on the two pancreatic carcinoma cell lines. In contrast, in the SK-OV-3 cell line, incubation with the two mAbs in combination resulted in a nearly complete inhibition of EGFR, while incubation with each mAb alone induced only minor inhibition.

Analysis of the inhibition of AKT and ERK1/2 phosphorylation was performed on the MiaPa-Ca-2 and SK-OV-3 cell lines. On the pancreatic carcinoma cell line, similar inhibitions of phosphorylation of the two intracellular signaling molecules were observed with anti-EGFR mAb alone, as with the two mAbs in combination, whereas in the ovarian carcinoma line, similar phosphorylation inhibitions were observed with the anti-HER2 mAb as with the two mAbs in combination.

These results, as well as more extensive *in vitro* studies from the literature (22-24), only partially explain the striking *in vivo* therapeutic synergism of the two anti-HER receptor Mabs against human carcinoma xenografts described here.

Discussion

In view of the present demonstration of the synergistic therapeutic effect of two anti-EGFR and -HER2 mAbs on two pancreatic carcinoma lines with moderate expression of HER2 and one ovarian carcinoma line overexpressing both HER receptors, we will consider the extent to which these experimental results may have an impact on the management of pancreatic and other types of carcinomas.

In pancreatic carcinoma, both EGFR and HER2 are known to be expressed in a significant percentage of the cases (5-8) and expression of these receptors has been shown to be involved in the initiation and progression of this tumor (5,7,28). Thus, in view of the toxicity and very modest results of the most advanced and intensive regimens of chemo- and radiotherapy in this type of cancer (4), it would seem logical to consider a combined treatment with the two anti-EGFR and anti-HER2 mAbs in patients with pancreatic carcinomas expressing even low levels of the two HER receptors.

In favor of the treatment of other types of carcinomas by the two anti-EGFR and -HER2 mAbs, the following arguments can be given: a) Treatment with each of the two anti-HER receptor mAbs has demonstrated clinical benefits, but rarely as a single modality therapy and mostly in conjunction with different forms of chemotherapy. The co-injection of a second anti-HER receptor mAb, which has the potential synergistic anti-tumor effect experimentally demonstrated here, appears more rational than the addition of a relatively non-specific chemotherapy. b) For the anti-HER2 mAb, it has been well established that the clinical benefits are limited to tumors with marked overexpression of the receptor (29), whereas in our experimental results, the synergism of anti-HER2 with anti-EGFR was demonstrated on two pancreatic carcinomas with low to moderate

HER2 expression. c) It has been shown in various carcinoma cell lines that treatment with small molecules inhibiting tyrosine kinase receptors, such as Iressa for EGFR (19) or the dual kinase inhibitor lapatinib for both EGFR and HER2 (16), can have a synergistic effect with anti-HER2 mAb treatment. However, the synergistic effect was mainly demonstrated *in vitro* and exclusively on target carcinoma lines overexpressing HER2. Furthermore, the effect of a small molecule with tyrosine kinase inhibitory property cannot be considered as identical to that of a large antibody molecule binding to the external domain of the receptors. d) For many years, several groups presented *in vitro* studies on tumor cells suspensions showing that simultaneous incubation with the two anti-EGFR and -HER2 mAbs induced more efficient inhibition of receptor phosphorylation and/or specific internalisation of the receptors, than incubation with one mAb alone (21-24). However, only one of the groups (23) tried a limited *in vivo* study with the two mAbs on one carcinoma cells line, which responded well to the anti-EGFR mAb alone, and thus failed to demonstrate any synergism between the two mAbs, while the other authors concluded that their *in vitro* studies may have important implications in cancer therapy (21,22,24).

Overexpression of HER2 is an established criteria tool to evaluate breast cancer patients for trastuzumab therapy (29,30), and accordingly, only patients with immunohistochemical 3+ HER2-tumor expression benefit from this mAb therapy. That is why it is so interesting that in the two pancreatic carcinoma xenografts tested here, expressing a very low level of HER2, the synergy of anti-HER2 with the anti-EGFR mAb gave a significant therapeutic advantage. For the EGFR, it is known that the correlation between the receptor expression and curative efficacy of anti-EGFR antibodies is not as clear as for HER2. The clinical response does not appear to correlate with the level of EGFR expression by

cancer cell, but preferentially with the receptor mutation, particularly in NSCLC (31). In this context, it should be noted that efficacy of the anti-HER2 mAb treatment alone, was superior to that of the anti-EGFR mAb alone in the HER2 overexpressing SK-OV-3 model and that in the MiaPaCa-2 xenograft expressing moderate amounts of EGFR the situation was reversed. However the novelty is that the two mAbs combination therapy gave significantly superior therapeutic results in the three human carcinoma xenograft models.

The results presented herein represent the first *in vivo* experimental demonstration of a long expected new improvement of cancer therapy by the synergistic action of two anti-EGFR and HER2 mAbs. Furthermore, our results suggest that a patient having breast carcinoma with moderate expression of HER2, who could not be treated with anti-HER2 mAb therapy, might benefit from the synergic treatment of the two anti-HER mAbs, provided that the tumor also expresses EGFR.

Three other cancer treatments based on the synergistic effect of two mAbs of different specificities are presently under investigation. First, a phase I clinical trial is underway for the treatment of non-Hodgkin's lymphoma with a combination of anti-CD20 and CD22 mAbs (32). The antigens recognized by these two mAbs are very different, however, and do not have the heterodimerization property, characteristic of the two HER receptors antibody targeted in our study (9,24). A second, entirely experimental, study involves an anti-insulin-like growth factor receptor (IGF-IR) mAb, which is reported to have a synergistic anti-tumor effect, either with a chemotherapeutic agent (vinorelbine) or with an anti-EGFR mAb, in a breast and a lung carcinoma xenograft model (33). This study is closer to ours since it involves two tyrosine kinase receptors and may implicate a similar synergism of two transducing factor pathways.

However, the IGF-IR does not belong to the HER receptor family and in terms of potential treatment, application IGF-IR is less tumor restricted than is the HER2 receptor. A third experimental study involves an anti-EGFR and an anti-VEGFR mAb in a pancreatic carcinoma xenograft model (34). This study is markedly different from ours since the two mAbs used are not directed against the same tumor target cells. Indeed, anti-VEGFR mAb binds to a receptor, which is expressed on endothelial cells, but not on pancreatic carcinoma cells (35). Thus the mechanism of action of the two mAbs in that study appears to be related to tumor vascularization parameters and is distinct from the binding of the two mAbs on two HER receptors located on the same target carcinoma cells, which seems responsible for the synergistic anti-tumor effect presented here.

Finally, a word of caution should be given before considering the combination of anti-EGFR and -HER2 mAbs for clinical application. In principle, the fact that the two mAbs react with two HER receptors known to be associated with malignant transformation should increase the tumor specificity of the treatment. However, since the combined mAb treatment presented here is active against tumor cells with a moderate expression of HER2, one could expect some new side effects, due to the fact that some normal tissues with a low HER2 expression, not sensitive to single anti-HER2 mAb, may become sensitive to the proposed combined mAb treatment.

REFERENCES

1. Wagner M, Redaelli C, Lietz M, et al. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. *Br J Surg* 2004;91:586-94.
2. Azria D, Ychou M, Jacot W, et al. Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil and cisplatin. *Pancreas* 2002;25:360-5.
3. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. *Lancet* 2004;363:1049-57.
4. Czito BG, Willett CG, Bendell JC, et al. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. *J Clin Oncol* 2006; 24:656-62.
5. Tobita K, Kijima H, Dowaki S, et al. Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis. *Int J Mol Med* 2003;11:305-9.
6. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. *J Clin Oncol* 2004;22:2610-6.
7. Day JD, Diguseppe JA, Yeo C, et al. Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. *Hum Pathol* 1996;27:119-24.
8. Saxby AJ, Nielsen A, Scarlett CJ, et al. Assessment of HER-2 status in pancreatic adenocarcinoma: correlation of immunohistochemistry, quantitative real-time RT-PCR, and FISH with aneuploidy and survival. *Am J Surg Pathol* 2005;29:1125-34.

9. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. *Nat Rev Cancer* 2005;5:341-54.
10. Schlessinger J. Cell signaling by receptor tyrosine kinases. *Cell* 2000;103:211-25.
11. Kumagai T, Davis JG, Horie T, O'Rourke DM, Greene MI. The role of distinct p185neu extracellular subdomains for dimerization with the epidermal growth factor (EGF) receptor and EGF-mediated signaling. *Proc Natl Acad Sci U S A* 2001;98:5526-31.
12. Qian X, O'Rourke DM, Fei Z, et al. Domain-specific interactions between the p185(neu) and epidermal growth factor receptor kinases determine differential signaling outcomes. *J Biol Chem* 1999;274:574-83.
13. King CR, Borrello I, Bellot F, Comoglio P, Schlessinger J. Egf binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SK-BR-3. *Embo J* 1988;7:1647-51.
14. Klapper LN, Glathe S, Vaisman N, et al. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. *Proc Natl Acad Sci U S A* 1999;96:4995-5000.
15. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. *Embo J* 1997;16:1647-55.
16. Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. *Cancer Res* 2006;66:1630-9.

17. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med* 2001;344:783-92.
18. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. *J Clin Oncol* 2000;18:904-14.
19. Normanno N, Campiglio M, De LA, et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. *Ann Oncol* 2002;13:65-72.
20. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets [see comments]. *Nat Med* 2000 6:443-6.
21. Klapper LN, Vaisman N, Hurwitz E, et al. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. *Oncogene* 1997;14:2099-109.
22. Ye D, Mendelsohn J, Fan Z. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. *Oncogene* 1999;18:731-8.
23. Kuwada SK, Scaife CL, Kuang J, et al. Effects of trastuzumab on epidermal growth factor receptor-dependent and -independent human colon cancer cells. *Int J Cancer* 2004;109:291-301.
24. Friedman LM, Rinon A, Schechter B, et al. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. *Proc Natl Acad Sci U S A* 2005;102:1915-20.
25. Vanhoefer U, Tewes M, Rojo F, et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000

in patients with advanced solid tumors that express the epidermal growth factor receptor. *J Clin Oncol* 2004;22:175-84.

26. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. *J Clin Oncol* 2005;23:1803-10.

27. Mimura K, Kono K, Hanawa M, et al. Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. *Clin Cancer Res* 2005;11:4898-904.

28. Dugan MC, Dergham ST, Kucway R, et al. HER-2/neu expression in pancreatic adenocarcinoma: relation to tumor differentiation and survival. *Pancreas* 1997;14:229-36.

29. Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. *Semin Oncol* 2001;28:13-9.

30. Press MF, Slamon DJ, Flom KJ, et al: Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. *J Clin Oncol* 2002;20:3095-105.

31. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2004;350:2129-39.

32. Leonard JP, Coleman M, Ketas J, et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. *J Clin Oncol* 2005;23:5044-51.

33. Goetsch L, Gonzalez A, Leger O, et al. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the

antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. *Int J Cancer* 2005;113:316-28.

34. Tonra JR, Deevi DS, Corcoran E, et al. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. *Clin Cancer Res* 2006;12:2197-207.

35. Li M, Yang H, Chai H, et al. Pancreatic carcinoma cells express neuropilins and vascular endothelial growth factor, but not vascular endothelial growth factor receptors. *Cancer* 2004;101:2341-50.

Acknowledgements

We thank G. Heintz, S. Bousquié, V. Garambois, P. Chuchana and R. Lavail for excellent technical assistance, M. Brissac and I. Aït-Arsa for help in performing the animal experiments and Dr S. L. Salhi for presubmission editorial assistance.

Table 1. Increment factor of BxPC-3 xenograft volume at the end of treatment in the small tumor (S) experiment

mAb	Treatment^a	Increment fact^b	% tumor free mice
-	C	8.0 ± 4.0	0
	M	4.9 ± 2.1	0
50	T	6.4 ± 4.4	0
	T+M	0.7 ± 0.5	25 (2/8)
-	C	21.3 ± 7.0	0
	M	4.3 ± 2.8	0
200	T	5.5 ± 2.1	0
	T+M	0.8 ± 0.3	60 (3/5)

^a C: control, M: matuzumab, T: trastuzumab, T+M: both mAbs.

^b Increment factor: (tumor volume at the end of treatment) / (tumor volume at the beginning of treatment).

Figure Legends


Figure 1. Immunohistochemical and flow cytometry analyses of EGFR and HER2 expression on the two pancreatic carcinoma xenografts, BxPC-3 and MiaPaCa-2, and on an ovarian xenograft SK-OV-3. NC (negative controls): tissues incubated only with the immunoperoxidase conjugate. In flow cytometry analyses, black and gray peaks depict cell surface staining with the anti-EGFR and the anti-HER2 antibodies, respectively. The white peaks represent controls, obtained with cells incubated only with the FITC-labeled second antibody.

Figure 2. Effects of trastuzumab and matuzumab alone or in combination on the growth of small size BxPC-3 xenografts in nude mice (experiment S). Mean pretreatment tumor volumes were $77 \pm 49 \text{ mm}^3$. Mice (eight per group) received i.p. injections of $50 \mu\text{g}$ of each mAb twice a week for four weeks. Results are expressed as tumor progression: $[(\text{final volume}) - (\text{initial volume})] / (\text{initial volume})$. C: control; T: trastuzumab; M: matuzumab; T+M: trastuzumab+matuzumab.


Figure 3. Effects of trastuzumab and matuzumab alone or in combination on the growth of large-size BxPC-3 xenografts in nude mice (experiment L). Mean pretreatment tumor volumes were $502 \pm 205 \text{ mm}^3$. Mice (five per group) received i.p. injections of $50 \mu\text{g}$ or $200 \mu\text{g}$ of each mAb twice a week for four weeks. A, Kaplan-Meier survival curves obtained as a function of time adapted for primary tumor to reach a volume of 1500 mm^3 . C: control; T: trastuzumab ($200 \mu\text{g}$ per injection); M: matuzumab ($200 \mu\text{g}$ per injection); T+M: trastuzumab+matuzumab (50 or $200 \mu\text{g}$ of each mAb per injection). B, results from the same experiments, expressed as tumor progression curves. Double head arrows indicate the treatment period.

Figure 4. Effects of trastuzumab and matuzumab alone or in combination on the growth of MiaPaCa-2 xenografts in nude mice. Mean (six per group) pretreatment tumor volumes were $64 \pm 5 \text{ mm}^3$. Mice received i.p. injections of 50 μg (**A**) or 25 μg (**B**) of each mAb twice a week for four weeks from day 15 to 43. A Kaplan-Meier survival curves obtained as a function of time adapted for primary tumor to reach a volume of 2000 mm^3 . C: control; T: trastuzumab; M: matuzumab; T+M: trastuzumab+matuzumab. **C**, Effects of trastuzumab and matuzumab alone or in combination on the growth of SK-OV-3 xenografts in nude mice. Mean (six per group) pretreatment tumor volumes were $42 \pm 4 \text{ mm}^3$. Mice received i.p. injections of 200 μg of each mAb twice a week for four weeks from day 11 to 40. A Kaplan-Meier survival curves for primary tumor to reach a volume of 1000 mm^3 . C: control; T: trastuzumab; M: matuzumab; T+M: trastuzumab+matuzumab


Figure 5. *In vitro* effect of trastuzumab and matuzumab alone or in combination on EGFR, HER2, ERK1/2 and AKT phosphorylation by western blot analysis. Cells were incubated or not with 10 $\mu\text{g}/\text{ml}$ of each mAb for 48 h followed by 10 min with 100 ng/ml of EGF or no EGF. For the BxPC-3 cell line, quantification of receptor phosphorylation, correlated to the GAPDH spot density and expressed in percent of control (cells without EGF treatment) are plotted as a bar graph and show the inhibition induced by the indicated treatment conditions. For the MiaPaCa-2 and SK-OV-3 cell lines, since the GAPDH spots density were constant in each experiment, no correlation with this control was necessary.




Larbouret et al. Figure 1.




Larbouret et al. Figure 2.



Larbouret et al. Figure 3.




Larbouret et al. Figure 4.



Larbouret et al. Figure 5.


Annex 1



Effects of trastuzumab and matuzumab alone or in combination on the growth of MiaPaCa-2 (A and B) and SK-OV-3 (C) xenografts in nude mice. Mice received i.p. injections of 25 µg (A), 50 µg (B) or 200 µg (C) of each mAb twice a week for four weeks. Results expressed as tumor growth curves. Double head arrows indicate the treatment period.

Annex 2


BxPC-3



xenograft	Treatments	EGFR expression		HER2 expression	
		% stained cells	Intensity	% stained cells	Intensity
BxPC-3	Control	90	3	0	0
		10	2		
	Trastuzumab	100	3	0	0
	Matuzumab	60	3	0	0
		20	2	0	0
	Trastuzumab + Matuzumab	70	3	0	0
		30	2	0	0

Effects of trastuzumab and matuzumab alone or in combination on EGFR and HER2 expression of BxPC-3 xenograft by immunohistochemical analysis. Tumors were analysed after 2 weeks of Treatments (50 μ g per injection)

SK-OV-3



xenograft	Treatments	EGFR expression		HER2 expression	
		% stained cells	Intensity	% stained cells	Intensity
SK-OV-3	Control	70	3	90	3
	Trastuzumab	90	3	90	3
	Matuzumab	70	3	90	3
		20	2	10	2
	Trastuzumab	60	3	50	3
	+ Matuzumab	30	2	50	2

Effects of trastuzumab and matuzumab alone or in combination on EGFR and HER2 expression of SK-OV-3 xenograft by immunohistochemical analysis. Tumors were analysed after 2 weeks of Treatments (200 μ g per injection)